spacer
home > ict > autumn 2016 > get involved
PUBLICATIONS
International Clinical Trials

Get Involved

Several studies have shown that applications of mHealth in healthcare settings have improved medication and procedural compliance (1); however, little research has been conducted on the effect of mHealth on clinical trial adherence and patient retention.

Clinical Ink piloted an mHealth sub-study with 30 subjects using a hybrid bring-your-own-device (BYOD)/provisioned device model, and results have indicated a low 6% subject dropout rate; a high average study procedure compliance of 84%; and high data quality. These data suggest that mHealth has an impact on reducing subject dropout rates, potentially improving protocol adherence and changing patient behaviour.

Research has shown that mHealth significantly enhances medication adherence, reduces non-adherence related adverse effects, and is accepted in healthcare in various geographic settings and among diverse demographic groups (1). Studies have also demonstrated that mHealth improves both recruitment and enrolment in clinical trials (2,3). Considering this with data showing nearly 43% of the global population and 68% of US adults owning a smartphone in 2015, advancing a BYOD approach (such as apps on a patient’s smartphone) in mHealth is inevitable (4,5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Kyle Hogan is eClinical Solutions Director with Clinical Ink, and is responsible for the strategic alignment of the company’s native mobile application for clinical trials. Kyle has delivered technical solutions for complex business challenges since the 1990s, and has more than nine years of experience in clinical trials.
spacer
Kyle Hogan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.

Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement